Earnings Call
Jul 15, 2026
Q2 FY2026
EPS Estimate
2.84
EPS Actual
2.90
Post-Earnings Close
$247.02
Earnings Reaction
-2.7%
Johnson & Johnson's second quarter delivered a clean beat on both the top and bottom line, with adjusted EPS of $2.90 against a consensus estimate of $2.85 and worldwide sales of $25.3 billion exceeding the $25.0 billion estimate. Management followed the results with a raise to full-year operational sales guidance, now $100.6 billion at the midpoint, up $400 million, and lifted adjusted operational EPS guidance to $11.50, $11.65, an $0.18 increase at the midpoint. The headline numbers, however, only partially capture the story: the quarter was defined by the accelerating momentum of a new product cycle that is beginning to structurally offset the well-telegraphed STELARA biosimilar erosion, which clocked in at a 55.7% decline but now represents just 4% of Innovative Medicine revenue.
Report generated on Jul 15, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full JNJ analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.